ArticleCancers2023

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.

Walter Hanel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.